Provided by Tiger Trade Technology Pte. Ltd.

Mineralys Therapeutics, Inc.

25.27
-0.3800-1.48%
Volume:591.20K
Turnover:15.01M
Market Cap:2.23B
PE:-5.77
High:25.86
Open:25.68
Low:24.95
Close:25.65
52wk High:47.65
52wk Low:14.53
Shares:88.16M
Float Shares:66.03M
Volume Ratio:0.64
T/O Rate:0.90%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.3763
EPS(LYR):-2.2900
ROE:-80.88%
ROA:-46.18%
PB:4.04
PE(LYR):-11.03

Loading ...

Mineralys CEO Jon Congleton sells 15,730 shares worth $421,988

Reuters
·
Apr 16

Mineralys CMO David Malcom Rodman sells 2,170 shares worth $59,405

Reuters
·
Apr 14

Mineralys Therapeutics announces annual shareholder meeting

Reuters
·
Apr 08

Mineralys CEO Jon Congleton disposes of USD 2.0 million common shares

Reuters
·
Apr 03

Mineralys director Daphne Karydas disposes of common shares worth $0.1 million

Reuters
·
Apr 03

RA Capital Management acquires $8.8 million Mineralys Therapeutics shares

Reuters
·
Apr 01

BUZZ-Immunic rises after board hire of MS drug veteran

Reuters
·
Mar 31

Mineralys appoints Jeffrey A. Munsie as chief legal officer

Reuters
·
Mar 24

Mineralys Therapeutics Appoints Jeffrey a. Munsie as Chief Legal Officer

THOMSON REUTERS
·
Mar 24

Press Release: Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer

Dow Jones
·
Mar 24

Mineralys Therapeutics (MLYS) Is Down 8.1% After Narrowed Loss, FDA Lorundrostat NDA Acceptance - What's Changed

Simply Wall St.
·
Mar 23

Mineralys CMO David Malcom Rodman disposes of USD 557,000 in common shares

Reuters
·
Mar 17

BRIEF-Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
Mar 17

Mineralys Therapeutics grants inducement equity awards covering 48,860 shares under 2025 plan

Reuters
·
Mar 17

Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS) and Aprea Therapeutics (APRE)

TIPRANKS
·
Mar 17

Mineralys Therapeutics, Inc. (MLYS) Receives a Buy from Wells Fargo

TIPRANKS
·
Mar 15

Stock Track | Mineralys Therapeutics Soars 5.26% Intraday on Bank of America's Buy Rating Reiteration

Stock Track
·
Mar 13

Bank of America Securities Sticks to Their Buy Rating for Mineralys Therapeutics, Inc. (MLYS)

TIPRANKS
·
Mar 13

Mineralys Therapeutics Q4 Loss Narrows

MT Newswires Live
·
Mar 13

Earnings Flash (MLYS) Mineralys Therapeutics Posts Q4 Loss of $0.40, vs. FactSet Est of $0.52 Loss

MT Newswires Live
·
Mar 13